(a) Histogram frequency distribution of CSF sPDGFRβ values using median split to divide participants into two groups with high (blue, above median 600-2,000 ng/ml) and low (grey, below median; 0-600 ng/ml) baseline CSF sPDGFRβ levels. All longitudinal analyses used baseline CSF sPDGFRβ as a continuous predictor of future cognitive decline. (b-c) Linear mixed model analysis of all studied participants (n=146) followed over 2-year intervals for up to 4.5 years after baseline lumbar puncture (LP) shows that higher baseline CSF sPDGFRβ (blue) predicts greater decline in demographically-corrected mental status exam scores over time (p=0.01), which remains significant after controlling for CSF Aβ (p=0.002) and pTau (p=0.002) status (b), and in global cognitive composite scores (p=0.01), which also remains significant after controlling for CSF Aβ (p=0.017) and pTau (p=0.01) status (c). (d-e) Higher CSF sPDGFRβ (blue) in APOE4 carriers (n=58) predicts future decline in mental status exam scores (p=0.005) after controlling for CSF Aβ (p=0.004) and pTau (p=0.003) status (d), and in global cognitive composite scores (p=0.02) after controlling for CSF Aβ (p=0.02) and pTau (p=0.01) status (e). (f-g) Baseline CSF sPDGFRβ does not predict decline in APOE3 homozygotes (n=88) on either mental status (f) or global composite (g) scores regardless of CSF Aβ or pTau status. Panels b-g, for graphical depiction, separate lines indicate median split of baseline CSF sPDGFRβ (grey, below median; blue, above median). ∆ slopes provided for median split of baseline CSF sPDGFRβ groups (grey, below median; blue, above median). Time was modeled as t0 = −1 to 0.5 years post-LP, t1 = 0.5 to 2.5 years post-LP, and t2 = 2.5 to 4.5 years post-LP. The error bars are SE of the estimate. In panels b-g, significance by linear mixed model analysis; no multiple comparison correction applied. See Supplementary Information Tables 2–4 for detailed statistics.